Relay Therapeutics, Inc. RLAY
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +106.15%
- 1 year
- +151.30%
- Market cap
- 3.82B
- Revenue (ttm)
- 10.35M
- EPS (ttm)
- -1.56
- Shares out
- 219.14M
- Forward P/E
- -10.68
- YTD return
- +106.15%
- 1-year return
- +151.30%
- Volume
- 3.18M
- Avg volume
- 2.78M
- Open
- 17.52
- Previous close
- 17.28
- Day's range
- 17.28 – 18.00
- 52-week range
- 5.95 – 21.27
- Beta
- 1.74
- Analysts
- Strong Buy
- Price target
- 27.58 (+58.2%)
- Earnings date
- Nov 4, 2026
YTD +9.26 (+113.20%)
Key statistics
- Enterprise value
- 2.91B
- PEG ratio
- 0.00
- Price / sales
- 369.26
- Price / book
- 4.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -48.30%
- Free cash flow
- -119.24M
- Total cash
- 910.93M
- Total debt
- 30.66M
- Return on equity
- -36.77%
- Short % of float
- 23.39%
- 50-day average
- 18.47
- 200-day average
- 15.05
Analyst view
Consensus: strong buy
- Target (low)
- 20.00
- Target (mean)
- 27.58
- Target (high)
- 32.00
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.40119.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.39639 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.39107 | -0.41 | -0.02 | -4.84% |
| May 5, 2026 | Mar 31, 2026 | -0.35 | -0.41 | -0.06 | -17.14% |
| Feb 26, 2026 | Dec 31, 2025 | -0.38 | -0.32 | +0.06 | +15.79% |
| Nov 6, 2025 | Sep 30, 2025 | -0.39 | -0.43 | -0.04 | -10.26% |
| Aug 7, 2025 | Jun 30, 2025 | -0.49 | -0.41 | +0.08 | +16.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Aug 10, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Aug 7, 2026 | Barclays | main | Overweight | Overweight |
| Jul 21, 2026 | Goldman Sachs | main | Buy | Buy |
| Jul 16, 2026 | Canaccord Genuity | init | — | Buy |
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- relaytx.com
News
Your note
Sign in to keep a note on RLAY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS BRIAN R | Officer | Sale | Jul 28, 2025 | 371,472 |
| BERGSTROM DONALD A. | Officer | Sale | Sep 7, 2026 | 399,130 |
| CATINAZZO THOMAS J | Chief Financial Officer | Sale | Oct 5, 2026 | 105,134 |
| PATEL SANJIV NARATANBHAI | Chief Executive Officer | Sale | Oct 6, 2026 | 1,358,200 |
| RAHMER PETER J | Officer | Sale | Aug 25, 2026 | 223,657 |
| SVF PAULING CAYMAN LTD | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 24, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SB Investment Advisers (UK) LTD | 12.73% | 27,904,963 | 486.66M | Jun 29, 2026 |
| FMR, LLC | 9.18% | 20,110,113 | 350.72M | Jun 29, 2026 |
| Casdin Capital, LLC | 7.32% | 16,035,240 | 279.65M | Jun 29, 2026 |
| Blackrock Inc. | 6.98% | 15,288,202 | 266.63M | Jun 29, 2026 |
| Perceptive Advisors Llc | 6.44% | 14,106,187 | 246.01M | Jun 29, 2026 |
| Commodore Capital Lp | 5.48% | 12,000,000 | 209.28M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.10% | 6,800,083 | 118.59M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.22% | 4,863,236 | 84.81M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.15% | 4,719,924 | 82.32M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.95% | 2,080,000 | 36.28M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.89% | 1,943,788 | 33.90M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 0.89% | 1,944,000 | 33.90M | Aug 30, 2026 |